AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26003545 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume strategy (8 to 10 ml/kg PBW)
Number of subjects: 0
Study 23174860 — intervention group
Group type: EXPERIMENTAL
Intervention: α(1)-blockade (prazosin, 1 mg/20 kg body wt)
Number of subjects: 12
Study 23174860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21636583 — intervention group
Group type: EXPERIMENTAL
Intervention: PI‐free combination including efavirenz
Number of subjects: 439
Study 21636583 — intervention group
Group type: EXPERIMENTAL
Intervention: PI‐free combination including nevirapine
Number of subjects: 439
Study 21636583 — intervention group
Group type: EXPERIMENTAL
Intervention: PI‐free combination including abacavir
Number of subjects: 439
Study 21636583 — intervention group
Group type: COMPARATOR
Intervention: First‐line boosted PI‐containing cART regimen (non-switch)
Number of subjects: 439
Study 19490035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 0
Study 19490035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day fixed-dosage
Number of subjects: 0
Study 19490035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17079377 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-on-alumina bearing system
Number of subjects: 146
Study 17079377 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium-on-polyethylene bearing system
Number of subjects: 146
Study 15580320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI)
Number of subjects: 119
Study 15580320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (cTnT)
Number of subjects: 119
Study 15580320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both troponins (cTnI and cTnT)
Number of subjects: 119
Study 11375376 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day)
Number of subjects: 30
Study 11375376 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9261853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (10 mg/kg/day for 10 days)
Number of subjects: 20
Study 9261853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8300814 — intervention group
Group type: COMPARATOR
Intervention: FSH‐HP preparation (sp. act. approximately 9000 IU FSH/mg of protein), administered as a single dose of 150 IU by i.v. injection to females and by i.m. and s.c. routes to males.
Number of subjects: 24
Study 8300814 — intervention group
Group type: COMPARATOR
Intervention: Standard urinary FSH preparation (Metrodin), administered as a single dose of 150 IU by i.v. injection to females and by i.m. and s.c. routes to males.
Number of subjects: 24
Study 3446307 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose flupenthixol decanoate
Number of subjects: 0
Study 3446307 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose flupenthixol decanoate
Number of subjects: 0
Study 29048235 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice condition
Number of subjects: 45
Study 29048235 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice condition
Number of subjects: 45
Study 29048235 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice condition
Number of subjects: 45
Study 26713491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation program (CTR) with individualized 3-month rehabilitation plan, home monitoring of blood pressure, pulse, weight, and steps taken.
Number of subjects: 151
Study 26713491 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation activities).
Number of subjects: 151
Study 24096802 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training with a commercial MRI simulator
Number of subjects: 222
Study 24096802 — intervention group
Group type: COMPARATOR
Intervention: Behavioral training with an inexpensive mock scanner
Number of subjects: 222
Study 24341465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothing Ventured Nothing Gained online adolescent and parenting intervention
Number of subjects: 120
Study 24341465 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study 20619405 — intervention group
Group type: EXPERIMENTAL
Intervention: Water method (n = 42)
Number of subjects: 82
Study 20619405 — intervention group
Group type: COMPARATOR
Intervention: Air method (n = 40)
Number of subjects: 82
Study 18845806 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose allopurinol (300 mg once a day)
Number of subjects: 50
Study 18845806 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose allopurinol (100 mg once a day)
Number of subjects: 50
Study 18845806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16339220 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg/day for 2 weeks
Number of subjects: 4373
Study 16339220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4373
Study 12652225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac tromethamine
Number of subjects: 114
Study 12652225 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 114
Study 10569560 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg avorelin subcutaneous depot
Number of subjects: 60
Study 10569560 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg avorelin subcutaneous depot
Number of subjects: 60
Study 8758317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily, n = 40)
Number of subjects: 84
Study 8758317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 84
Study 2071786 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 527
Study 2071786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise on a treadmill
Number of subjects: 527
Study 2071786 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic individuals
Number of subjects: 527
Study 2071786 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma subgroup
Number of subjects: 527
Study 6753112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 0.1 mg.kg-1
Number of subjects: 8
Study 6753112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 0.25 mg.kg-1
Number of subjects: 8
Study 6753112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 0.5 mg.kg-1
Number of subjects: 8
Study 6753112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg.kg-1)
Number of subjects: 8
Study 6753112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (various doses)
Number of subjects: 8
Study 31078402 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched dialysis fluid
Number of subjects: 6
Study 31078402 — intervention group
Group type: COMPARATOR
Intervention: Standard high-flux HD
Number of subjects: 6
Study 29042241 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia crowns
Number of subjects: 30
Study 29042241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic crowns
Number of subjects: 30
Study 29042241 — intervention group
Group type: COMPARATOR
Intervention: Enamel controls
Number of subjects: 30
Study 27029956 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Taping (KT)
Number of subjects: 44
Study 24800828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent killed whole-cell oral cholera vaccine
Number of subjects: 137
Study 24800828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 22222120 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiji practice
Number of subjects: 70
Study 22222120 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 70
Study 20008945 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care management intervention
Number of subjects: 407
Study 20008945 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study 18029497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 12 weeks
Number of subjects: 0
Study 18029497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fish oil supplementation)
Number of subjects: 0
Study 18029497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (subgroup analysis)
Number of subjects: 0
Study 16044225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngoscopy
Number of subjects: 12
Study 16044225 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory examination
Number of subjects: 12
Study 16044225 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and auditory evaluations
Number of subjects: 12
Study 16044225 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by less experienced raters
Number of subjects: 12
Study 16044225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohens Kappa coefficient
Number of subjects: 12
Study 11907287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 347
Study 11907287 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine
Number of subjects: 347
Study 11907287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (for patients with dispatch to drug administration ≤ 24 minutes)
Number of subjects: 347
Study 11907287 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (for patients with dispatch to drug administration ≤ 24 minutes)
Number of subjects: 347
Study 9464213 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of CCK‐4
Number of subjects: 80
Study 9464213 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 8582218 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum gastrin measurement
Number of subjects: 24
Study 8582218 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic acid output (BAO) measurement
Number of subjects: 24
Study 8582218 — intervention group
Group type: EXPERIMENTAL
Intervention: Free portal pressure (FPP) measurement
Number of subjects: 24
Study 8582218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroduodenoscopy and barium series
Number of subjects: 24
Study 8582218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroduodenoscopy
Number of subjects: 24
Study 2746444 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine spray, applied twice a day
Number of subjects: 14
Study 2746444 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash, rinsed twice a day
Number of subjects: 14
Study 769242 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine
Number of subjects: 16
Study 769242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31437399 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational approach using nudged elastic band (NEB) and harmonic Fourier beads (HFB) methods for studying loop dynamics.
Number of subjects: 0
Study 31437399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence anisotropy measurements.
Number of subjects: 0
Study 31437399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence T-jump measurements.
Number of subjects: 0
Study 31437399 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted Trp354 conformational conversion associated with loop movements.
Number of subjects: 0
Study 27686946 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy (75 mg/m2 once daily for 21 days, repeated every 28 days for a maximum of 12 cycles)
Number of subjects: 477
Study 27686946 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for up to 6.5 weeks)
Number of subjects: 477
Study 27686946 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 477
Study 27686946 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy
Number of subjects: 477
Study 27686946 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 477
Study 25027459 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan coated sutures
Number of subjects: 2400
Study 25027459 — intervention group
Group type: COMPARATOR
Intervention: Standard non-coated sutures
Number of subjects: 2400
Study 22343176 — intervention group
Group type: EXPERIMENTAL
Intervention: Azidothymidine
Number of subjects: 64
Study 22343176 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride
Number of subjects: 64
Study 22343176 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 64
Study 20696729 — intervention group
Group type: EXPERIMENTAL
Intervention: Early transition group (transferred from incubator to open crib at >1600 g)
Number of subjects: 94
Study 20696729 — intervention group
Group type: COMPARATOR
Intervention: Standard transition group (transferred from incubator to open crib at >1800 g)
Number of subjects: 94
Study 20696729 — intervention group
Group type: EXPERIMENTAL
Intervention: Early transition group
Number of subjects: 94
Study 20696729 — intervention group
Group type: COMPARATOR
Intervention: Standard transition group
Number of subjects: 94
Study 18463880 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridology assessment of patients with colorectal cancer
Number of subjects: 58
Study 18463880 — intervention group
Group type: COMPARATOR
Intervention: Iridology assessment of healthy control subjects
Number of subjects: 58
Study 16313106 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangni Hewei Decoction (JHD), one dose per day for 8 weeks
Number of subjects: 75
Study 16313106 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, 20 mg once per day for 8 weeks
Number of subjects: 75
Study 12893712 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium concentration (680 mg/l)
Number of subjects: 13
Study 12893712 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium concentration (410 mg/l)
Number of subjects: 13
Study 12893712 — intervention group
Group type: COMPARATOR
Intervention: Water (no sodium)
Number of subjects: 13
Study 9457940 — intervention group
Group type: EXPERIMENTAL
Intervention: T (50‐100 mg IM weekly) + desogestrel (150‐300 microg daily)
Number of subjects: 15
Study 9457940 — intervention group
Group type: EXPERIMENTAL
Intervention: T (50‐100 mg IM weekly) + levonorgestrel (125‐250 microg daily)
Number of subjects: 15
Study 9457940 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 1907565 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH
Number of subjects: 16
Study 1907565 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study 6310812 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 37
Study 6310812 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 37
Study 6310812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 37
Study 30677095 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal belt wearing group (B)
Number of subjects: 36
Study 30677095 — intervention group
Group type: COMPARATOR
Intervention: Non-abdominal belt wearing control group (C)
Number of subjects: 36
Study 30134976 — intervention group
Group type: EXPERIMENTAL
Intervention: Suite of videos for advance care planning
Number of subjects: 0
Study 30134976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic adaptations to implementation approach
Number of subjects: 0
Study 27113442 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone-delivered cognitive behavioural therapy (tCBT)
Number of subjects: 473
Study 27113442 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 473
Study 24246900 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous consent condition
Number of subjects: 200
Study 24246900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-anonymous consent condition
Number of subjects: 200
Study 24246900 — intervention group
Group type: COMPARATOR
Intervention: Traditional consent condition
Number of subjects: 200
Study 24246900 — intervention group
Group type: EXPERIMENTAL
Intervention: Certificates of Confidentiality (CoC) condition
Number of subjects: 200
Study 24246900 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional distress disclosure
Number of subjects: 200
Study 23366836 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 5
Study 23366836 — intervention group
Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 5
Study 20717108 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin (SG)
Number of subjects: 80
Study 20717108 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 80
Study 17729384 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation (HoLEP)
Number of subjects: 0
Study 17729384 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 0
Study 17729384 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP and TURP
Number of subjects: 0
Study 15713598 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 of each 28-day cycle (3w4)
Number of subjects: 174
Study 15713598 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,500 mg/m² on days 1 and 8 of each 21-day cycle (2w3)
Number of subjects: 174
Study 15713598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 174
Study 11812915 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO, epoetin)
Number of subjects: 0
Study 11812915 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9428213 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide (6.75 g daily)
Number of subjects: 101
Study 7554207 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 287
Study 7554207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 287
Study 7554207 — intervention group
Group type: COMPARATOR
Intervention: Pump-prime-only aprotinin
Number of subjects: 287
Study 7554207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 2167008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 (spermicide)
Number of subjects: 818
Study 2167008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 818
Study 6992010 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine HCl (Duranest) 1%
Number of subjects: 50
Study 6992010 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine HCl (Xylocaine) 2% with epinephrine 1:200,000
Number of subjects: 50
Study 31608448 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 281
Study 31608448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 30975498 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced stapler
Number of subjects: 200
Study 30975498 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic dissector
Number of subjects: 200
Study 28422779 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 21
Study 28422779 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 21
Study 27044782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound simulation (SonoSim)
Number of subjects: 53
Study 27044782 — intervention group
Group type: COMPARATOR
Intervention: Hands-on training with live models
Number of subjects: 53
Study 27044782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 24439092 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroModulation Technique (NMT) - two sessions a week for six weeks
Number of subjects: 18
Study 24439092 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group - two sessions a week for six weeks after the wait period
Number of subjects: 18
Study 22906581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotz plate treatment
Number of subjects: 30
Study 22906581 — intervention group
Group type: COMPARATOR
Intervention: No Hotz plate treatment
Number of subjects: 30
Study 19064373 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D Supplementation (active)
Number of subjects: 36282
Study 19064373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 36282
Study 17324249 — intervention group
Group type: EXPERIMENTAL
Intervention: R667 0.2 mg
Number of subjects: 40
Study 17324249 — intervention group
Group type: EXPERIMENTAL
Intervention: R667 0.5 mg
Number of subjects: 40
Study 17324249 — intervention group
Group type: EXPERIMENTAL
Intervention: R667 1 mg
Number of subjects: 40
Study 17324249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with narrow filter (580-650 nm) at fluence rate of 30 mW cm(‐2)
Number of subjects: 37
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with narrow filter (580-650 nm) at fluence rate of 45 mW cm(‐2)
Number of subjects: 37
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with broad filter (580-690 nm) at fluence rate of 50 mW cm(‐2)
Number of subjects: 37
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with broad filter (580-690 nm) at fluence rate of 75 mW cm(‐2)
Number of subjects: 37
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with cumulative light dose of 40 J cm(‐2)
Number of subjects: 37
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with varying fluence rates from 30 to 75 mW cm(‐2)
Number of subjects: 37
Study 15606516 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with cumulative light dose of 20 J cm(‐2)
Number of subjects: 37
Study 11688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra Mobiele Zylinder implants (IMZ group, n = 41)
Number of subjects: 87
Study 11688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implants (Brå group, n = 17)
Number of subjects: 87